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Abstract
Background: It is well known that osteopontin (OPN) plays an important role in tumor progression and that a
high OPN expression level in several tumor entities correlates with poor prognosis in cancer patients. However,
little is known about the prognostic relevance of the OPN mRNA splice variants.
Methods: We analyzed the mRNA expression levels of different OPN splice variants in tumor tissue of 124 soft
tissue sarcoma (STS) patients. Quantitative real-time PCR (qRT-PCR) was used to analyze the mRNA expression level
of three OPN splice variants (OPN-a, -b and -c).
Results: The multivariate Cox’s proportional hazard regression model revealed that high mRNA expression levels of
OPN splice variants are significantly associated with poor prognosis in STS patients (n = 124). Women (n = 68) with
high mRNA expression levels of OPN-a and OPN-b have an especially elevated risk of tumor-related death (OPN-a:
RR = 3.0, P = 0.01, CI = 1.3-6.8; OPN-b: RR = 3.4, P = 0.01, CI = 1.4-8.2). In particular, we found that high mRNA
expression levels of OPN-b and OPN-c correlated with a high risk of tumor-related death in STS patients that
received radiotherapy (n = 52; OPN-b: RR = 10.3, P < 0.01, CI = 2.0-53.7; OPN-c: RR = 11.4, P < 0.01, CI = 2.2-59.3).
Conclusion: Our study shows that elevated mRNA expression levels of OPN splice variants are negative prognostic
and predictive markers for STS patients. Further studies are needed to clarify the impact of the OPN splice variants
on prognosis.
Background
Osteopontin is a secreted phosphoprotein that plays an
important role in tumor progression. It affects processes
such as cellular growth, cell migration, invasion, metasta-
sis and decay of the extracellular matrix [1]. Several stu-
dies showed that an increased OPN expression correlates
with poor prognosis in cancer patients [2-4]. However,
only a few studies have analyzed the importance of OPN
for tumor progression in sarcomas. OPN protein expres-
sion level was shown to be elevated in tumor cells, and
high OPN levels were associated with high tumor stage,
tumor grade and poor survival in sarcoma patients [5-7].
Additionally, Bramwell et al. (2005) showed that OPN
mRNA is also overexpressed in the tumor tissue of STS
patients. In a previous study, we demonstrated that
higher OPN protein expression levels in tumor tissue and
serum were associated with worse prognosis in STS
patients [8].
Young et al. (1990) identified three splice variants of
OPN, but their specific functions remained unclear. In
addition to the full-length form osteopontin-a (OPN-a)
with 7 exons, there are the splice variants osteopontin-b
(OPN-b) and osteopontin-c (OPN-c) with deletions of
exon 5 and exon 4, respectively. The first in vitro studies
demonstrated a different impact of the OPN splice var-
iants on cell migration, invasion, apoptosis and prolifera-
tion in various cancer cell lines [9-13]. Compared to
normal tissue, the tumor tissues of different cancer entities
express higher levels of OPN splice variants [10,12,14-18].
However, only one study, which investigates breast cancer
patients, analyzed the prognostic impact of the OPN splice
variants [15]. In the present study, we analyzed the prog-
nostic relevance of the expression level of the three OPN
splice variants (OPN-a, -b and -c) in the tumor tissue of
124 STS patients.
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Patients and tissue samples
We analyzed the frozen primary tumor samples of 124
STS patients and surrounding tissue of 15 STS patients
by qRT-PCR for the mRNA expression of OPN splice
variants (partially described in [8]). The clinical and his-
tomorphological parameters of the STS patients are
shown in Table 1. In total, 50.8% of STS patients (n = 63)
were still alive after an average follow-up time of 57.3
(range 9-198) months, and 49.2% of STS patients (n =
61) died from tumor-related reasons after an average of
28.0 (range 2-201) months. The tumors were staged
according to the Union for International Cancer Control
(UICC) system. All patients gave their written informed
Table 1 Clinical and histomorphological data
Parameter Total (n = 124) OPN-a mRNA expression OPN-b mRNA expression OPN-c mRNA expression
low (n = 62) high (n = 62) low (n = 62) high (n = 62) low (n = 62) high (n = 62)
Sex P = 0.02 P = 0.10 P = 0.37
Male 56 35 21 33 23 31 25
Female 68 27 41 29 39 31 37
Histological subtype P = 0.96 P = 0.17 P = 0.17
Liposarcoma 27 14 13 14 13 13 14
MFH/Fibrosarcoma 38 17 21 14 24 14 24
N S 1 5879696
RMS + LMS 29 15 14 14 15 15 14
other STS 15 8 7 11 4 11 4
Tumor grade P = 0.03 P = 0.05 P = 0.03
I 16 6 10 6 10 4 12
II 70 42 28 42 28 42 28
III 37 13 24 14 23 16 21
Tumor stage P = 0.37 P = 0.43 P = 0.33
I 1 578785 1 0
II 57 33 24 33 24 33 24
III 40 18 22 17 23 19 21
I V 1 2485757
Tumor localization P = 0.29 P = 0.26 P = 0.30
Extremities 79 37 42 37 42 36 43
Thorax 12 575766
Head and neck 4 131313
Abdominal 27 18 9 17 10 18 9
Other 2 112011
Recurrence P = 1.00 P = 1.00 P = 1.00
Yes 55 28 27 28 27 27 28
No 69 34 35 34 35 35 34
Lymph node status P = 0.21 P = 0.21 P = 0.03
N0 118 61 57 61 57 62 56
N 1 6 151506
Distant metastases P = 0.28 P = 0.88 P = 0.88
M0 45 25 20 23 22 23 2
M1 50 20 30 24 26 24 26
Evaluation not possible 3 212121
Radiation P = 1.00 P = 0.86 P = 0.86
Yes 58 29 29 30 28 30 28
No 66 33 33 32 34 32 34
Chemotherapy P = 0.74 P = 0.74 P = 0.74
Y e s 1 0464646
No 114 58 56 58 56 58 56
Abbreviations: MFH - malignant fibrous histiocytoma, NS - neurogenic sarcoma, RMS - rhabdomyosarcoma, LMS - leiomyosarcoma
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Page 2 of 7consent to the Institute of Pathology, University of Halle,
Germany, and Department of Surgery 1, University of
Leipzig, Germany. The study was approved by the Ethics
Committee of the Medical Faculty of the Martin-Luther-
University Halle-Wittenberg and is in compliance with
the Helsinki Declaration.
RNA preparation, cDNA synthesis and transcript analysis
by quantitative real-time PCR (qRT-PCR)
The total RNA of the frozen tissue samples was isolated by
the Trizol method (Invitrogen, Karlsruhe, Germany), and
the cDNA was prepared using the RevertAid™ HM i n u s
First Strand cDNA Synthesis Kit (Fermentas, St.Leon-Rot,
Germany) according to the manufacturer’si n s t r u c t i o n s .
All qRT-PCR reactions were performed on a Rotorgene
RG-6000 (LTF, Wasserburg, Germany) using the Quanti-
Tect SYBRGreen PCR Kit (Fermentas). The primer
sequences of the OPN splice variants and specific anneal-
ing temperatures are summarized in Table 2 (previously
described in [14]). HPRT (hypoxanthine-guanine phos-
phoribosyltransferase) was used as a housekeeping gene
(for standardization) and a marker for integrity of the
cDNA. All methods were previously described in detail [8].
Statistical analysis
The statistical analysis was carried out using SPSS 17.0
(SPSS Inc., Chicago, IL, USA). Spearman’sr h ot e s tw a s
used for bivariate linear regression analyses. For survival
analysis, the Kaplan-Meier method and the multivariate
Cox’s proportional hazard regression model were applied
with appropriate adjustment to tumor type, tumor stage
and tumor localization. We used a log-rank test to com-
pare the survival curves of Kaplan-Meier analysis and to
test for statistical differences. A two-tailed Fisher’s exact-
test or chi-square test was performed to determine the
associations between mRNA expression level of OPN
splice variants and different clinical parameters. A Wil-
coxon signed-rank test was used to analyze the statistical
differences of the 15 paired tumor and normal tissues. For
survival analysis and comparison with clinical parameters,
the cut-off values were set according to the median of
mRNA expression levels of OPN splice variants (Table 3).
Ap r o b a b i l i t y≥ 95% (P ≤ 0.05) was considered an indicator
of a significant difference between mean values.
Results and discussion
mRNA expression levels of OPN splice variants in STS
tissues
The analysis of mRNA expression levels of OPN splice var-
iants in the tumor tissues of 124 STS patients reveals a
median transcript ratio of 0.68 copies OPN-a mRNA/
copies HPRT mRNA (range: 9.30*10
-4-85.29), 0.49 copies
OPN-b mRNA/copies HPRT mRNA (range: 0.00-17.64)
and 0.082 copies OPN-c mRNA/copies HPRT mRNA
(range: 0.00-4.03). Comparison of the OPN splice variants
mRNA expression levels clearly showed that OPN-a and
OPN-b are expressed at a distinctly higher level than
OPN-c (both with P < 0.01). The lower expression level of
OPN-c is consistent with the findings in hepatocellular car-
cinoma, breast cancer and mesothelioma [12,15,16].
Furthermore, using bivariate linear Spearman-Rho correla-
tion, we found a significant correlation of the mRNA
expression levels between all OPN splice variants (r = 0.84-
0.95, all with P < 0.01). Additionally, the mRNA expression
level of total OPN and OPN splice variants show a weak
correlation (n = 65, OPN-a: r = 0.32, P < 0.01; OPN-b: r =
0.30, P = 0.02; OPN-c: r = 0.26, P = 0.04).
In surrounding tissues of 15 STS patients we calculated
a median transcript ratio of 0.66 copies OPN-a mRNA/
copies HPRT mRNA (range: 5.80*10
-2-30.19), 0.19 copies
OPN-b mRNA/copies HPRT mRNA (range: 7.20*10
-3-
3.98) and 0.034 copies OPN-c mRNA/copies HPRT
mRNA (range: 9.55*10
-4-0.67). The median mRNA
expression levels of OPN splice variants reveal that OPN-
b and OPN-c in paired tumor tissues are expressed on a
higher level compared to surrounding tissues (n = 15, p =
0.07 and p = 0.06). Figure 1 demonstrates a 2.9 and 3.4-
fold increased mRNA expression level of OPN-b and
OPN-c in tumor tissues. However, OPN-a mRNA expres-
sion level was not increased in tumor tissues (1.2-fold,
p = 0.80). Several other studies confirm in tumor tissues a
higher mRNA expression level of OPN splice variants
Table 2 Primers for quantitative real-time RT-PCR
Gene Primer Sequence 5’ ® 3’ Localization Annealing temperature
HPRT HPRT309 5’-TTGCTGACCTGCTGGATTAC-3’ sense 391-410 58°C
HPRT507 5’-CTTGCGACCTTGACCATCTT-3’ antisense 633-652
OPN-a OPN-a fw 323 5’-ATCTCCTAGCCCCACAGAAT-3’ sense 323-342 58°C
OPN-a rev 508 5’-CATCAGACTGGTGAGAATCATC-3’ antisense 529-508
OPN-b OPN-b fw 323 5’-ATCTCCTAGCCCCACAGAC-3’ sense 323-341 62°C
OPN-b rev 509 5’-AAAATCAGTGACCAGTTCATCAG-3’ antisense 531-509
OPN-c OPN-c fw 246 5’-TGAGGAAAAGCAGAATGCTG-3’ sense 246-265 58°C
OPN-c rev 377 5’-GTCAATGGAGTCCTGGCTGT-3’ antisense 396-377
Sequences and localization of primers used in this study correspond to mRNA sequences of HPRT [Genbank: NM_000194.2], OPN-a [Genbank: NM_001040058.1],
OPN-b [Genbank: NM_000582.2] and OPN-c [Genbank: NM_001040060.1]
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ment with our analysis, in breast cancer and ovarian can-
cer, especially OPN splice variants OPN-b and OPN-c are
expressed on elevated mRNA levels compared to sur-
rounding or normal tissues [10,14,15,18].
Bivariate linear analyses of mRNA expression levels of
OPN splice variants with clinical and histomorphological
parameters
Examinations of the relation of mRNA expression levels of
OPN splice variants with clinical and histomorphological
parameters revealed a significant correlation of the mRNA
expression level of OPN-a with sex and tumor grade
( T a b l e1 ) .M o r em a l ep a t i e n t sh a v eal o wO P N - am R N A
expression level compared to female patients (P = 0.02,
Table 1). Grade 3 tumors are strongly associated with high
mRNA expression levels of OPN-a, OPN-b and OPN-c (P
= 0.03, P = 0.05 and P = 0.03, respectively). The mRNA
expression levels of the OPN splice variants were also sig-
nificantly higher in high-grade gliomas than in low-grade
gliomas [9,17]. Recently, Patani et al. (2008) verified that
the mRNA expression levels of OPN-b and OPN-c were
also increased with higher tumor grade in breast cancer.
Furthermore, we found that all patients with lymph node
metastases had a significantly higher OPN-c mRNA
expression level (P = 0.03). It is well known that OPN-c
mediates anchorage independence and tumor invasion
[10,21], which are crucial processes for the development of
metastases. Several studies showed that OPN-c is
expressed at higher levels in invasive tumor cells compared
to noninvasive tumor cells [13,14,17,21]. Furthermore, it
has been demonstrated in these studies that OPN-c influ-
ences the expression of several migration/invasion markers,
such as MMP-2, MMP-9 and uPA, which promote tumor
cell invasion. This is in accordance with the correlation we
found between the OPN splice variants, the uPA, uPAR
and PAI mRNA and the protein expression levels in STS
(data not shown). Previously, we could show that the pro-
tein levels of uPA, uPAR and PAI in tumor tissue and
serum are also associated with poor prognosis of STS
patients [22]. However, we found no correlation between
the mRNA expression level of OPN splice variants and the
tumor stage, histological tumor subtype (Additional file 1),
tumor localization or recurrence.
mRNA expression levels of OPN splice variants and
disease-associated survival
We performed multivariate Cox’s proportional hazard
regression analysis to study the correlation between
OPN splice variant levels and tumor-specific survival.
Table 3 Kaplan-Meier analyses and multivariate Cox’s regression analyses
STS patients OPN splice variant n Median values
[copies OPN splice
variant mRNA/
copies HPRT mRNA]
Kaplan-Meier analysis multivariate Cox’s regression model
Survival [months] P RR P CI
All OPN-a low 62 0.68 90
OPN-a high 62 71 1.7 1.7 0.06 1.0-3.0
OPN-b low 62 0.49 117
OPN-b high 62 66 0.13 2.1 0.02 1.2-3.6
OPN-c low 62 0.08 94
OPN-c high 62 81 0.38 1.8 0.04 1.0-3.1
Female OPN-a low 34 0.83 116
OPN-a high 34 53 0.08 3.0 0.01 1.3-6.8
OPN-b low 34 0.58 102
OPN-b high 34 42 0.13 3.4 < 0.01 1.4-8.2
OPN-c low 34 0.09 92
OPN-c high 34 46 0.50 2.3 0.07 0.9-5.4
RT patients OPN-a low 26 0.65 80
OPN-a high 26 76 0.04 3.5 0.07 0.9-13.0
OPN-b low 26 0.42 147
OPN-b high 26 55 0.05 10.3 < 0.01 2.0-53.7
OPN-c low 26 0.07 147
OPN-c high 26 55 0.05 11.4 < 0.01 2.2-59.3
Association of the mRNA expression of OPN splice variants in different groups of patients (all STS patients, females and RT patients) with overall survival. The
median values of OPN-a, OPN-b and OPN-c were used as cut-off points to divide the STS patients into two groups: one with high and one with low (reference
group) OPN mRNA levels in tumor tissues
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the three OPN splice variants have a worse prognosis
than those with low mRNA expression levels in their
tumors. An elevated mRNA expression level of OPN-b
or OPN-c is significantly correlated with a 2.1-fold or
1.8-fold increased risk of tumor-related death for STS
patients, respectively (P = 0.02, CI = 1.2-3.6; P = 0.04,
CI = 1.0-3.1) (Table 3). The mRNA expression level of
OPN-a shows an association trend with the prognosis of
STS patients (RR = 1.7, P = 0.06) (Table 3). Addition-
ally, STS patients had worst prognosis when all OPN
splice variants are expressed on high mRNA levels (data
not shown). A study on 15 adult STS patients found a
significant increase of total OPN mRNA levels in tumor
tissues compared to normal tissues [5]. Another study
on 41 osteosarcoma patients reported that higher OPN
mRNA levels were associated with a worse prognosis
[23]. However, our preceding data of 68 STS patients
revealed that mRNA expression level of whole OPN did
not significantly correlate with prognosis [8]. Up to
n o w ,t h ep r o g n o s t i cr e l e v a n c eo ft h eO P Ns p l i c ev a r -
iants was only determined for breast cancer patients.
The breast cancer patients with high mRNA expression
levels of OPN-b or OPN-c had significantly shorter sur-
vival times than those with low mRNA expression levels
[15]. Because we found much lower mRNA expression
levels of OPN-a in the tumors of male patients (n = 56)
than in those of female patients (n = 68), we performed
sex-specific survival analyses (Table 3 and Figure 2A.).
A multivariate Cox’s regression model also revealed that
female STS patients have a significantly worse prognosis
than male STS patients. The women with high OPN-a
or OPN-b mRNA expression levels have a 3.0-fold (P =
0.01, CI = 1.3-6.8) or 3.4-fold (P < 0.01, CI = 1.4-8.2)
increased risk of tumor-related death, respectively. The
different prognostic impact of the mRNA expression
level in men and women is possibly caused by hormonal
regulation of mRNA expression by female sex hormones
or hormone receptors [24].
Therapy of STS patients comprises surgical removal of
the tumor and treatment with radio- and/or chemother-
apy. To investigate the prognostic impact of the mRNA
expression level of OPN splice variants prior to radiother-
apy, we analyzed STS patients who received a curative
radiotherapy (n = 52) (RT patients). In the Kaplan-Meier
analysis, we found that the RT patients with low mRNA
expression levels of all OPN splice variants have a signifi-
cant survival benefit compared to those with high mRNA
expression levels in their tumors (P < 0.05, Table 3). In
addition multivariate Cox’s regression models revealed
that RT patients with high mRNA expression levels of
OPN-b and OPN-c have a 10.3-fold and 11.4-fold
increased risk of tumor-related death, respectively (P <
0.01, CI = 2.0-53.7; P < 0.01, CI = 2.2-59.3) (Figure 2B.,
Table 3). In the STS patients who did not receive radio-
therapy (n = 62), the mRNA expression level of the OPN
splice variants had no prognostic importance (data not
shown). Consequently, the inhibiting of OPN could pro-
vide an additional survival benefit for STS patients who
are treated with radiotherapy. Similarly, Overgaard et al.
(2005) found that high OPN plasma concentrations are
associated with a poor prognosis in patients with head and
neck cancer after radiotherapy [25]. Our in vitro study ver-
ified the association of OPN and radiotherapy and proved
that the inhibition of OPN mRNA expression increases
the radiosensitivity of the mamma carcinoma cells [26].
Conclusions
In the present study, we found for the first time that the
mRNA expression levels of OPN-b and OPN-c were sig-
nificantly correlated with the clinical outcome of STS
patients. Our data demonstrate that female STS patients
and RT patients with low mRNA expression levels of
OPN splice variants have a distinct survival benefit. In
fact, the different roles of the OPN splice variants in
angiogenesis, cellular invasion, cancer progression, and
metastasis are widely discussed in the literature
[14,17,18,21,27]. Further studies are needed to clarify
why OPN splice variants have different effects on the
prognosis of cancer patients.
Figure 1 Comparison of mRNA expression of OPN splice
variants in surrounding and tumor tissue. The boxplot shows
the relative mRNA expression levels of OPN-a, OPN-b and OPN-c in
tumor and paired surrounding tissues of 15 STS patients. The
boxplot displays the median value of each data set, which is
indicated by the centerline. The edges of the boxes represent the
25th percentile and 75th percentile. The 10th and 90th percentiles
are marked through the horizontal lines outside the boxes. Circles
and asterisks mark outliers (1.5 to 3 box lengths from the edge of
the boxes) and far outliers (more than 3 lengths from the edge of
the boxes).
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levels of OPN splice variants are negative prognostic and
predictive markers, particularly for female STS patients
and those who receive curative radiotherapy. However,
more data are necessary to evaluate the OPN splice var-
iants in the clinical management of STS patients.
Additional material
Additional file 1: Median mRNA expression level of the OPN splice
variants in the different histotypes of soft tissue sarcoma.
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